2026年美国临床肿瘤学会（ASCO）年会将于5月29日至6月3日在美国芝加哥举行。作为全球规模最大的肿瘤学研究盛会之一，2026 年 ASCO 年会头颈部肿瘤领域的学术趋势已明确从“是否有药可用”转向“如何精准组合”。特别是中国学者在鼻咽癌治疗细节上的深耕，以及全球范围内对新型 ADC 和双抗药物在头颈部鳞癌中的尝试，正不断刷新该领域的生存数据上限。目前大会官网已公布摘要标题，【肿瘤资讯】特此整理了本届大会中头颈部肿瘤领域的重磅口头报告的最新研究成果，以飨读者。
Oral Abstract Session
英文标题：Amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell cancer after disease progression on immune checkpoint inhibitor and chemotherapy: Pivotal results from the phase 1b/2 OrigAMI-4 study.
中文标题：Amivantamab 用于免疫检查点抑制剂和化疗进展后的 HPV 阴性复发/转移性头颈部鳞状细胞癌：I b/II 期 OrigAMI-4 研究的关键结果
讲者：Barbara Burtness
摘要号：6008
英文标题：Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.
中文标题：超低剂量免疫治疗联合口服节律化疗对比紫杉醇-卡铂治疗铂类敏感的复发或转移性头颈部鳞状细胞癌：一项随机 III 期试验
讲者：Minit Jalan Shah
摘要号：LBA6007
英文标题：Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST; CTRI/2017/07/009114).
中文标题：早期口腔鳞状细胞癌根治术后辅助放疗对比观察（AREST 研究；CTRI/2017/07/009114）
讲者：Sudhir Vasudevan Nair
摘要号：6000
英文标题：Impact of lymph node dissection extent on disease-free survival with postoperative nivolumab plus concurrent chemoradiotherapy in head and neck squamous cell carcinoma: A post-hoc analysis of the NIVOPOSTOP trial.
中文标题：淋巴结清扫范围对纳武利尤单抗联合同步放化疗术后辅助治疗头颈部鳞状细胞癌无病生存率的影响：NIVOPOSTOP 试验的后验分析
讲者：Ariane Lapierre
摘要号：6001
英文标题：A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck.
中文标题：Ipatasertib 联合帕博利珠单抗一线治疗复发或转移性头颈部鳞状细胞癌的 II 期研究
讲者：Jacob Stephen Thomas
摘要号：6006
英文标题：Two-cycle versus three-cycle induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase IIl randomized noninferiority trial.
中文标题：两周期对比三周期诱导化疗序贯同步放化疗治疗局部晚期鼻咽癌：一项 III 期随机非劣效性试验
讲者：中山大学肿瘤防治中心梁虎教授
摘要号：6003
英文标题：Carboplatin-based versus cisplatin-based induction-concurrent chemoradiotherapy with locoregionally advanced nasopharyngeal carcinoma: A multicenter, parallel-group, non-inferiority, randomized, phase 3 trial.
中文标题：基于卡铂对比基于顺铂的诱导-同步放化疗治疗局部晚期鼻咽癌：一项多中心、平行分组、非劣效性、随机、III 期试验
讲者：南方医科大学南方医院官键教授
摘要号：6004
英文标题：Metronomic adjuvant chemotherapy (MACE) in locally advanced oral cavity squamous cell carcinoma post-surgery and adjuvant treatment (MACE postop): A phase Ill randomized controlled trial.
中文标题：节律辅助化疗（MACE）在局部晚期口腔鳞状细胞癌术后及辅助治疗中的应用（MACE postop）：一项 III 期随机对照试验
讲者：Nandini Sharrel Menon
摘要号：6002
英文标题：Adjuvant sintilimab-capecitabine versus capecitabine alone in locoregionally advanced nasopharyngeal carcinoma with suboptimal response to induction chemotherapy: An open-label, randomized, controlled, phase 2 trial.
中文标题：信迪利单抗联合卡培他滨对比单用卡培他滨辅助治疗诱导化疗反应不佳的局部晚期鼻咽癌：一项公开标签、随机、对照、II 期试验
讲者：待定（中山大学肿瘤防治中心刘丽婷教授团队）
摘要号：LBA6005
Rapid Oral Abstract Session
英文标题：Timing of postoperative chemoradiotherapy and survival outcomes in high-risk locally advanced head and neck squamous cell carcinoma: A supplementary analysis of JCOG1008.
中文标题：高危局部晚期头颈部鳞状细胞癌术后放化疗的时机与生存结局：JCOG1008 研究的补充分析
讲者：Yoshinori Imamura
摘要号：6015
英文标题：Nivolumab plus lenvatinib for unresectable anaplastic thyroid cancer: Results of the phase 2 NAVIGATION study.
中文标题：纳武利尤单抗联合仑伐替尼治疗不可切除的未分化甲状腺癌：II 期 NAVIGATION 研究的结果
讲者：Makoto Tahara
摘要号：6021
英文标题：Phase Il study of izalontamab (SI-B001) in combination with paclitaxel or docetaxel in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
中文标题：Izalontamab (SI-B001) 联合紫杉醇或多西他赛治疗复发/转移性 (R/M) 头颈部鳞状细胞癌 (HNSCC) 的 II 期研究
讲者：上海市东方医院郭晔教授
摘要号：6019
英文标题：Final analysis of the investigator-initiated randomized study of anti–PD-L1 durvalumab (durva) with radiation versus chemoradiation (CRT) for intermediate-risk HPV-positive (HPV+) locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC): Canadian Cancer Trials Group (CCTG) HN.9 (EORTC 1740-HNCG).
中文标题：抗 PD-L1 药物度伐利尤单抗 (Durva) 联合放疗对比放化疗 (CRT) 治疗中危 HPV 阳性局部晚期口咽鳞状细胞癌 (LA-OPSCC) 的研究者发起随机研究的最终分析：加拿大癌症试验组 (CCTG) HN.9 (EORTC 1740-HNCG)
讲者：Anna Spreafico
摘要号：6017
英文标题：Phase II randomized trial of radiotherapy with pembrolizumab vs. cisplatin for unfavorable-risk p16+ head and neck squamous cell carcinoma (KEYCHAIN).
中文标题：放疗联合帕博利珠单抗对比顺铂治疗不良风险型 p16+ 头颈部鳞状细胞癌的 II 期随机试验 (KEYCHAIN)
讲者：Loren K. Mell
摘要号：6016
英文标题：Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin (AP) for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory phase II study.
中文标题：依沃西单抗（Ivonescimab, AK112, 一种 PD-1/VEGF 双特异性抗体）联合白蛋白紫杉醇和顺铂 (AP) 新辅助治疗可切除的局部晚期头颈部鳞状细胞癌 (LA-HNSCC)：一项探索性 II 期研究
讲者：华中科技大学同济医学院附属协和医院杨坤禹教授
摘要号：6014
英文标题：FID -007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
中文标题：FID-007 联合西妥昔单抗治疗复发或转移性 (R/M) 头颈部鳞状细胞癌 (HNSCC)
讲者：Guilherme Rabinowits
摘要号：6020
英文标题：Randomized phase I/lI trial adjuvant CD40.HVAC, an immunotherapy engaging dendritic cells (DC), in patients with HPV16+ oropharyngeal carcinoma (OPC).
中文标题：辅助性 CD40.HVAC（一种通过树突状细胞发挥作用的免疫疗法）治疗 HPV16+ 口咽癌 (OPC) 患者的随机 I/II 期试验
讲者：Caroline Even
摘要号：6018
英文标题：Induction chemotherapy with nab-paclitaxel and cisplatin versus docetaxel, cisplatin, and fluorouracil followed by chemoradiotherapy in patients with stage lIl-IVA nasopharyngeal carcinoma: An open-label, noninferiority, randomized, controlled, phase 3 trial.
中文标题：白蛋白紫杉醇联合顺铂对比多西他赛、顺铂及氟尿嘧啶（TPF）诱导化疗序贯放化疗治疗 III-IVA 期鼻咽癌患者：一项公开标签、非劣效性、随机、对照、III 期试验
讲者：中山大学肿瘤防治中心Haoyang Huang教授
摘要号：6013
Clinical Science Symposium
英文标题：Trastuzumab deruxtecan in patients with HER2-low recurrent/metastatic salivary gland carcinoma: Results from the phase Il MYTHOS trial.
中文标题：德曲妥珠单抗 (Trastuzumab deruxtecan) 用于 HER2 低表达复发/转移性唾液腺癌患者：II 期 MYTHOS 试验的结果
讲者：Ichiro Kinoshita
摘要号：6011
英文标题：A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy-naive recurrent and/or metastatic androgen receptor (AR)-positive salivary gland cancer (ETCTN 10553).
中文标题：达罗他胺联合醋酸亮丙瑞林治疗激素初治的复发和/或转移性雄激素受体 (AR) 阳性唾液腺癌的 II 期研究 (ETCTN 10553)
讲者：Alan Loh Ho
摘要号：6012
英文标题：Emiltatug ledadotin (Emi-Le), a B7-H4-directed antibody-drug conjugate (ADC), in patients with aggressive adenoid cystic carcinoma (ACC): Phase 1 interim analysis.
中文标题：Emiltatug ledadotin (Emi-Le, 一种针对 B7-H4 的抗体偶联药物) 用于侵袭性腺样囊性癌 (ACC) 患者：I 期中期分析
讲者：Glenn J. Hanna
摘要号：6010
英文标题：Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the phase 1/2 dose-escalation cohort.
中文标题：MYB mRNA 降解剂 REM-422 在复发/转移性腺样囊性癌中的临床活性：I/II 期剂量爬坡队列的最终结果
讲者：Renata Ferrarotto
摘要号：6009
排版编辑：肿瘤资讯-lcm
苏公网安备32059002004080号
